Orphan Drug Designation EU | Work process

June 8, 2022

The Orphan Drug Designation (ODD) is a status assigned by EMA to a medicine intended for use against a rare condition. The medicine must fulfil certain criteria for designation as an orphan medicine so that it can benefit from incentives such as protection from competition once on the market.

We have summarized the work process for you to have always at hand.

Have a look at the complete process:

ODD Key facts Asphalion

For further information, queries or assistance, contact us at: info@asphalion.com

 

 

 

 

Search News & Events

  • Filter by category

Share

Related news and events

HORIZON | siNPAIN meeting in Reykjavík

The objective of this project is to create a siRNA-combined advanced therapy, which will allow a more personalised treatment for different stages of osteoarthritis.  All siNPAIN partners are working hard to develop efficient therapy to improve the quality of life of those affected by osteoarthritis, a chronic joint condition that affects more and more people every year.

For further information

If you are interested in our services, or wish to get in touch for a general enquiry, please contact us for more information.

Fill the form and we will contact you as soon as possible.

You can also follow us on:

Schedule a Free Meeting

Schedule here a free 30-minutes meeting with one of our consultants and tell us about your project, challenges or doubts. 

We will be happy to assist you!

Schedule a meeting